Stocktoria
Biofrontera Inc. BFRI
Biofrontera Inc. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $41.7M | $37.3M | $34.1M | $28.7M | $24.1M | $18.8M |
| R&D expense | $3.7M | $2.1M | $77,000 | — | — | — |
| SG&A expense | $37.8M | $33.8M | $39.0M | $35.1M | $36.5M | $17.7M |
| Operating income | -$11.3M | -$17.2M | -$22.7M | -$18.6M | -$25.2M | -$9.6M |
| Interest expense | — | — | $220,000 | $12,000 | $344,000 | $2.9M |
| Income tax | $25,000 | $22,000 | $14,000 | $32,000 | $56,000 | $64,000 |
| Net income | -$10.5M | -$17.8M | -$20.1M | -$640,000 | -$37.7M | -$11.0M |
| EPS (diluted) | $-1.04 | $-3.22 | $-13.02 | $-0.61 | — | — |
| Operating cash flow | -$13.4M | -$10.3M | -$24.9M | -$16.2M | -$26.7M | -$12.4M |
| Free cash flow | -$13.4M | -$10.3M | -$24.9M | -$16.2M | — | — |
| Cash & equivalents | $6.4M | $5.9M | $1.3M | $17.2M | $24.5M | $8.1M |
| Inventory | $1.4M | $6.6M | $10.9M | $7.2M | $4.5M | $7.1M |
| Total assets | $28.6M | $22.1M | $27.9M | $50.9M | $53.2M | $24.1M |
| Total liabilities | $18.1M | $17.7M | $23.1M | $27.0M | $41.9M | $18.3M |
| Shareholders' equity | $10.5M | $4.4M | $4.8M | $23.9M | $11.3M | $5.8M |
Growth · year-over-year · Revenue CAGR 17.2%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | +11.7% | +9.5% | +18.8% | +19.0% | +27.9% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.